haxxiy on 11 July 2022
In phase I and II clinical trials, the monovalent Omicron vaccines performed better than the bivalent ones. I feel there's no point in keeping the original formulation when people have had multiple doses of the stuff and Omicron elicits a robust recall response of the wild-type antibodies. That'd be a disappointing shot.
Unless it'd be a BA.1/BA.2 bivalent shot. Then we'd be talking.
